CANCER SCREENING AND PREVENTION: A GLOBAL PERSPECTIVE ON CURRENT PRACTICES, CHALLENGES, AND FUTURE DIRECTIONS

Authors

  • Meena Gyawali MPH, MPRHGD,Asia International University, Bukhara, Uzbekistan Author

Keywords:

Cancer prevention, cancer screening, early detection, public health, global health, cancer control.

Abstract

Cancer remains a leading cause of morbidity and mortality worldwide, accounting for nearly 20 million new cases and 9.7 million deaths in 2022. Effective cancer prevention and screening strategies have significantly reduced the burden of several common malignancies through early detection and risk-factor modification. Primary prevention measures, including tobacco control, vaccination against oncogenic viruses, healthy lifestyle promotion, and environmental protection, play a critical role in reducing cancer incidence. Secondary prevention through organized screening programs for cervical, breast, colorectal, and lung cancers facilitates early diagnosis and improved survival outcomes. Despite substantial progress, major disparities persist between high-income and low- and middle-income countries (LMICs) regarding access to screening services, healthcare infrastructure, public awareness, and resource allocation. Emerging technologies such as artificial intelligence, molecular diagnostics, liquid biopsy, and risk-stratified screening offer promising opportunities to enhance effectiveness and accessibility. This review examines the current global landscape of cancer prevention and screening, highlights existing challenges, and discusses future directions aimed at reducing cancer-related morbidity and mortality worldwide.

References

1.Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2024. CA Cancer J Clin. 2024;74(3):229-263.

2.Wild CP, Weiderpass E, Stewart BW. World Cancer Report: Cancer Research for Cancer Prevention. Lyon: IARC; 2020.

3.World Health Organization. Cancer: Key Facts. Geneva: WHO; 2025.

4.Islami F, Goding Sauer A, Miller KD, Siegel RL, Fedewa SA, Jacobs EJ, et al. Proportion and number of cancer cases attributable to potentially modifiable risk factors. CA Cancer J Clin. 2018;68(1):31-54.

5.Jha P. The hazards of smoking and benefits of cessation. N Engl J Med. 2020;382(8):717-731.

6.Drolet M, Bénard É, Pérez N, Brisson M. Population-level impact of HPV vaccination programmes. Lancet. 2019;394(10197):497-509.

7.World Health Organization. Cancer Prevention Overview. Geneva: WHO; 2024.

8.Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body fatness and cancer. N Engl J Med. 2016;375(8):794-798.

9.Schüz J, Espina C, Villain P, Herrero R, Leon ME, Minozzi S, et al. European Code Against Cancer. Cancer Epidemiol. 2015;39(Suppl 1).

10.World Health Organization. Global Strategy to Accelerate the Elimination of Cervical Cancer. Geneva: WHO; 2020.

11.Nelson HD, Fu R, Cantor A, Pappas M, Daeges M, Humphrey L. Effectiveness of breast cancer screening. JAMA. 2016;314(15):1615-1634.

12.Shaukat A, Kahi CJ, Burke CA, Rabeneck L, Sauer BG, Rex DK. ACG Clinical Guidelines: Colorectal Cancer Screening 2021. Am J Gastroenterol. 2021;116(3):458-479.

13.National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409.

14.Sankaranarayanan R, Basu P, Kaur P, Bhaskar R, Singh GB, Denzongpa P, et al. Current status of cancer screening in developing countries. Lancet Oncol. 2019;20(11).

15.Topol EJ. High-performance medicine: convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56.

Downloads

Published

2026-06-09